Year in Review | Published:

Renal vasculitis in 2012

Reclassification and the introduction of biologicals

Nature Reviews Nephrology volume 9, pages 7072 (2013) | Download Citation

2012 saw the classification of the systemic vasculitides revised. Genetic studies showed that granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are different diseases with aberrant immune responses to different autoantigens. B-cell depletion with rituximab also acquired a primary role in the treatment of GPA and MPA, as well as in cryoglobulinaemic vasculitis.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. .

  2. 2.

    et al. Genetically distinct subsets within ANCA-associated vasculitis. N. Engl. J. Med. 367, 214–223 (2012).

  3. 3.

    et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 349, 36–44 (2003).

  4. 4.

    et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann. Intern. Med. 150, 670–680 (2009).

  5. 5.

    et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann. Rheum. Dis. 71, 955–960 (2012).

  6. 6.

    et al. Long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 64, 3472–3477 (2012).

  7. 7.

    et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221–232 (2010).

  8. 8.

    et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's). Arthritis Rheum. 64, 3770–3778 (2012).

  9. 9.

    et al. Management of noninfectious mixed cryoglobulinemic vasculitis: data from 242 cases included in the CryoVas survey. Blood 119, 5996–6004 (2012).

  10. 10.

    et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 64, 843–853 (2012).

Download references

Acknowledgements

The author's work is supported by the European Union Seventh Framework Programme (FP7/2007-2013) grant number 261382.

Author information

Affiliations

  1. Department of Rheumatology & Clinical Immunology, University of Groningen, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands.  c.g.m.kallenberg@umcg.nl

    • Cees G. M. Kallenberg

Authors

  1. Search for Cees G. M. Kallenberg in:

Competing interests

The author declares no competing financial interests.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrneph.2012.284

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing